The risk of PML from natalizumab - Authors' reply
Lancet Neurol
.
2019 Mar;18(3):230-231.
doi: 10.1016/S1474-4422(19)30022-5.
Epub 2019 Feb 12.
Authors
Pei-Ran Ho
1
,
Nolan Campbell
2
,
Ih Chang
2
Affiliations
1
Biogen, Cambridge, MA 02142, USA. Electronic address: peiran.ho@biogen.com.
2
Biogen, Cambridge, MA 02142, USA.
PMID:
30784549
DOI:
10.1016/S1474-4422(19)30022-5
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
JC Virus / immunology*
Leukoencephalopathy, Progressive Multifocal*
Multiple Sclerosis*
Natalizumab
Retrospective Studies
Substances
Natalizumab